Theralase Technologies Inc. V.TLT

The best competition has to offer

[enriquesuave]

72% CR and 59% durable CR response at 12 months or better. Combination of N-803 with BCG. Combination drugs offer uneven comparison but gives us an idea of the most competitive treatment modality. This is still many more treatments using standard BCG protocol plus N-803 so about 12-15 treatments or more and has more side effects. But still very good outcome. If we match or beat their numbers we will shine as the next gold standard. Imo. Much more patient friendly just can't afford any screw ups. 

https://immunitybio.com/category/press-releases/

[CancerSlayer]

  Those are impactful %s and agree...this is our biggest competitor.  Just want to clarify the 59% reported was the "percentage probability" of maintaining a CR at 12 months.  This percentage would actually equate to a 42% durable CR at 12 months.  Still commendable, but makes for a more conquerable target.  Also, I believe the total number of treatments could

[CancerSlayer]

There were 51 responders out of a total of 71 evaluable patients & a reported 59% probability those 51 responders would maintain a durable CR.  This would be 0.59 X 51 = 30 patients.  30 of 71 total evaluable patients = 42% durable response at 12 months.

[enriquesuave]

Nice catch on CR rate. 42% makes sense now.  Ok we can easily beat that I hope 

[fredgoodwinson]

If 13, 14 and their successors mimic 5 & 6 there may not even need to be a second treatment, just a precautionary cystoscopy at 6 months to ensure that there remains ‘no clinical evidence or presence of disease’.   Contrast this with the cost and logistical burden on public health and the detriment to the well-being of often elderly and unwell patients that accompany the many

[CancerSlayer]

  Hit the nail on the head Fred...great post. I also suspect a significant percentage of patients may not even require a 2nd treatment...just a follow-up assessment/surveillance, a grateful bye bye, & then live a long healthy life with a lot more spending money.  No contest for sure imo.

[Johnandrose22]

I agree with your simple analysis. At this point, the study hinges on patients 13 and 14 because they could/should mimic the protocol of patients 5 and 6. All eyes should be on results of these two going forward. John

[fredgoodwinson]

Thanks J&R. Perhaps excessively simplistic in that in cases of re-seeding from the UUT a second and possibly further treatment might be required (would these resolve the remote tumour?) but for the majority eventually just the one and essentially yes - 13 &14. Surely most carefully selected after the preceding debacle. No hiding place and in the case of NMIBC - win or bust.

[CancerSlayer]

  Would be interesting to see if the immune response generated by PDT of the bladder has any impact on UUT cancer.  If little or no response, there may be utility in using IV Rutherrin followed by PDT via ureteroscopy (for early & distal cancers of the ureter) or via laparoscopy for all other UUT cancers.  And if Theralase can ultimately utilize photosensitizer activation by

[fredgoodwinson]

Agreed Cancer Slayer - didn`t read your latest before I`d posted mine but the generation of a systemic immune response is the goal and a second treatment should be part of the protocol for this reason alone. The further methods that you propose are most interesting.This is some powerful tech.  

[skier59]

Hi HempDoc, nice to have you back posting ;)